These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14638652)

  • 1. Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.
    Laupacis A; Paterson JM; Mamdani M; Rostom A; Anderson GM
    CMAJ; 2003 Nov; 169(11):1167-70. PubMed ID: 14638652
    [No Abstract]   [Full Text] [Related]  

  • 2. Health Canada proposes new regulatory regime for drugs.
    Kondro W
    CMAJ; 2007 Apr; 176(9):1261-2. PubMed ID: 17452653
    [No Abstract]   [Full Text] [Related]  

  • 3. Post-market approval surveillance: a call for a more integrated and comprehensive approach.
    Mehran R; Leon MB; Feigal DA; Jefferys D; Simons M; Chronos N; Fogarty TJ; Kuntz RE; Baim DS; Kaplan AV
    Circulation; 2004 Jun; 109(25):3073-7. PubMed ID: 15226222
    [No Abstract]   [Full Text] [Related]  

  • 4. [Study designs for the evaluation of drug effects].
    Christensen S; Christiansen CF; Sørensen HT
    Ugeskr Laeger; 2009 Mar; 171(10):799-802. PubMed ID: 19265605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing studies of drug efficacy.
    Strom BL; Melmon KL; Miettinen OS
    Arch Intern Med; 1985 Oct; 145(10):1791-4. PubMed ID: 3899034
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug surveillance. Which methods? For which adverse effects? Application to teratogen monitoring].
    Goujard J
    Therapie; 1985; 40(5):287-92. PubMed ID: 4095683
    [No Abstract]   [Full Text] [Related]  

  • 7. Health Canada's Progressive Licensing Framework.
    Yeates N; Lee DK; Maher M
    CMAJ; 2007 Jun; 176(13):1845-7. PubMed ID: 17576983
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative effectiveness research: drug-drug comparisons in heart failure.
    Fosbol EL
    Heart Fail Clin; 2013 Jan; 9(1):37-47. PubMed ID: 23168316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: a personal viewpoint.
    Rawson NS
    Pharmacoepidemiol Drug Saf; 2002 Jun; 11(4):335-40; discussion 341-2. PubMed ID: 12138603
    [No Abstract]   [Full Text] [Related]  

  • 10. [Critical study of methods of postmarketing drug surveillance].
    Gut JP; Auriche M; Spriet-Pourra C; Juillet Y
    Therapie; 1985; 40(5):313-9. PubMed ID: 3913048
    [No Abstract]   [Full Text] [Related]  

  • 11. [The use observation--an observation of use. Does it have to be published?].
    Fortunat S
    Dtsch Med Wochenschr; 2003 Oct; 128(42):2215; author reply 2215. PubMed ID: 14562224
    [No Abstract]   [Full Text] [Related]  

  • 12. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of conventional drugs and biologic agents for Rheumatoid Arthritis.
    Amoroso A; Gigante A; Gianni C; Amoroso D; Zennaro D; Galluzzo S; Caccavo D
    Eur Rev Med Pharmacol Sci; 2003; 7(5):139-45. PubMed ID: 15214589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bayesian approach to the imputability of undesirable phenomena to drugs].
    Auriche M
    Therapie; 1985; 40(5):301-6. PubMed ID: 4095686
    [No Abstract]   [Full Text] [Related]  

  • 16. [Practical value of active prospective monitoring of drug therapy safety].
    Ovchinnikova EA; Nazimkin KE; Iagudina RI
    Antibiot Khimioter; 2006; 51(9-10):40-6. PubMed ID: 18030790
    [No Abstract]   [Full Text] [Related]  

  • 17. Re-examining our approach to the approval and use of new drugs.
    Lee SK
    CMAJ; 2006 Jun; 174(13):1855. PubMed ID: 16785460
    [No Abstract]   [Full Text] [Related]  

  • 18. The desire to regulate: the wish to discover.
    Lasagna L
    Drugs Exp Clin Res; 1987; 13(11):659-64. PubMed ID: 3443041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expert consensus post-marketing evaluation scheme to detect immunotoxicity of Chinese medicine in clinical populations (draft version for comments)].
    Xie YM; Zhao YB; Jiang JJ; Chang YP; Zhang W; Shen H; Lu PF
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2933-6. PubMed ID: 24471307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood dyscrasias and the pharmaceutical industry: screening surveillance and monitoring, and future drug development.
    Eur J Haematol Suppl; 1996; 60():128-9. PubMed ID: 8987256
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.